INCY

Incyte Corporation News Headlines

$87.91
*  
0.04
0.05%
Get INCY Alerts
*Delayed - data as of Mar. 4, 2015  -  Find a broker to begin trading INCY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    INCY Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Eli Lilly Maintains '14 View, Growth to Resume in 2015 - Analyst Blog
1/8/2015 12:29:00 PM - Investopedia


Eli Lilly Maintains '14 View, Growth to Resume in 2015 - Analyst Blog
1/8/2015 12:29:00 PM - Zacks.com


Alexion Reports Disappointing Phase II Data on Soliris - Analyst Blog
1/8/2015 4:45:00 AM - Investopedia


Biodel Posts Positive Preliminary Data on its Diabetes Drug - Analyst Blog
1/8/2015 4:00:00 AM - Investopedia


Alkermes Soars on Positive Schizophrenia Drug Results - Analyst Blog
1/8/2015 3:50:00 AM - Investopedia


Alkermes Gains on Positive Depression Drug Study Data - Analyst Blog
1/7/2015 5:10:00 PM - Zacks.com


Gilead to Purchase Liver Disease Program from Phenex - Analyst Blog
1/7/2015 4:45:00 PM - Zacks.com


Celsion Submits Study Protocol for Oncology Candidate - Analyst Blog
1/7/2015 4:20:00 PM - Zacks.com


Incyte Corporation (INCY): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
1/7/2015 7:00:00 AM - Investopedia


Alkermes Gains on Positive Depression Drug Study Data - Analyst Blog
1/7/2015 5:10:00 AM - Investopedia


Gilead to Purchase Liver Disease Program from Phenex - Analyst Blog
1/7/2015 4:45:00 AM - Investopedia


Celsion Submits Study Protocol for Oncology Candidate - Analyst Blog
1/7/2015 4:20:00 AM - Investopedia


Minerva Neurosciences' MIN-301 Positive in Primate Study - Analyst Blog
1/6/2015 7:20:00 PM - Zacks.com


Akebia Progresses with Chronic Kidney Disease Candidate - Analyst Blog
1/6/2015 5:00:00 PM - Zacks.com


Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog
1/6/2015 1:50:00 PM - Investopedia


Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog
1/6/2015 1:50:00 PM - Zacks.com


Salix CEO to Step Down, Inventory Issues Remain in Focus - Analyst Blog
1/6/2015 10:50:00 AM - Investopedia


Salix CEO to Step Down, Inventory Issues Remain in Focus - Analyst Blog
1/6/2015 10:50:00 AM - Zacks.com


Minerva Neurosciences' MIN-301 Positive in Primate Study - Analyst Blog
1/6/2015 7:20:00 AM - Investopedia


Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst Blog
1/5/2015 4:30:00 PM - Zacks.com


Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst Blog
1/5/2015 4:30:00 AM - Investopedia


Zacks' Bull Of The Day: Incyte
1/2/2015 7:02:00 AM - Seeking Alpha


Bull of the Day: Incyte (INCY) - Bull of the Day
1/2/2015 1:00:00 AM - Zacks.com


Bull of the Day: Incyte (INCY) - Bull of the Day
1/1/2015 1:00:00 PM - Investopedia


Will Biotech Fire On All Cylinders In 2015?
12/30/2014 4:15:00 PM - Seeking Alpha